🔗 Share this article

As the US undertakes historic revisions to its vaccine guidelines, an unexpected name has emerged in a surprising turn: Høeg, a US-based sports physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccines during the global health crisis and has zeroed in on possible deaths following COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Schedule

Agency leaders had intended to reveal major changes to the pediatric vaccine schedule in December, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US out of step with many the international standard with little proof for benefit. The planned update has been postponed until the coming year.

Rather than Vinay Prasad, Dr. Høeg is listed to present at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

Consolidating Power at the FDA

Høeg's temporary position might represent a strengthened alliance between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing some pediatric immunization guidelines in the US to become more like Denmark's approach, a society with comprehensive healthcare and a number of inhabitants approximately the size of Wisconsin’s.

To date comments, she has kept her attention on immunizations – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Questions Over Expertise

Dr. Høeg has no apparent background in drug development, oversight or administrative roles, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a large organization. She lacks background in industry regulation.”

Former heads of the center would “understand legal statutes and the research of medication creation”, noted a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that previous people who ran the center have had.”

This division has an enormous range of responsibilities at the FDA, the former commissioner pointed out.

“Many people just pays attention on the novel medication approvals, but the generic drug division clears a multitude of generic medications. There’s a biosimilars program, over-the-counter program and other areas, and every single one must be managed,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a substantial administrative component to the position, which oversees over 5,000 employees. “It is a enormous leadership role, if you execute it properly,” she said.

Agency Reaction and Disputed Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this selection represents greater collaboration among FDA leaders on immunizations, a press secretary said that the “questions are based on incorrect assumptions”.

“This background is consistent with the functions of her job,” the spokesperson explained, citing the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg inherits the commissioner’s controversial priority voucher program, a controversial one-day drug-approval program that allegedly worried her predecessors. “By what process are these medications being selected for this voucher program? Who makes the choices?” Howard said. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, except for vaccines.”

Established Track Record on Vaccines

With immunizations, Høeg has a more established, if problematic, history, some experts observe. She published a analysis using unconfirmed public submissions to determine the incidence of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the new government featured changing regulations for novel immunizations and ending “non-essential” immunizations, she remarked post-election on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of excluding adolescent males from getting Covid vaccines.

“She’s an all-around dogmatist who starts off with her preconceived notions and reverse-engineers to fit the science in a extremely deceptive, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|